ClinicalTrials.gg
RecruitingNCT03557619Updated Aug 29, 2024

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

A Phase 1 interventional study of Venetoclax and ethinyl estradiol/levonorgestrel in Hematologic Malignancies, sponsored by AbbVie. Recruiting at 4 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
531st of 658
12 · median 40
Started
2019
with 36 others
Phase 1
195 of 821
35 open now
Primary completion
2026-03
later than 58 of 273 live
Registered
416th of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 531st largest by planned enrollment of the 658 interventional ones that give a count, is one of 37 that started in 2019, is one of 195 in phase 1, reaches primary completion later than 58 of the 273 other live ones, and was the 416th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study.

03

Conditions studied

  • Hematologic Malignancies

Keywords

  • Cancer
  • Hematologic Malignancies, venetoclax
  • ethinyl estradiol
  • relapsed or refractory non-Hodgkin's lymphoma
  • non-Hodgkin's lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have non-Hodgkin's lymphoma (NHL).
  • Participant must have documented diagnosis of one of the following NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), T-cell prolymphocytic lymphoma (T-PLL), Waldenström's macroglobulinemia (WM)
  • Has an (ECOG) performance score of less than or equal to two.
  • Must have adequate bone marrow, coagulation, renal and hepatic function as described in the protocol.
  • A female of non- as described in the protocol.

Exclusion criteria

Exclusion Criteria:

  • History of currently active, cardiovascular disease.
  • If the participant has had prior stem cell transplantation, it must have been more than 100 days prior to start of study drug, with no , and no therapy.
  • evidence of transformation of the lymphoma immediately prior to study entry.
  • Evidence of central nervous system involvement by lymphoma.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Ethinyl estradiol/Levonorgestrel and Venetoclax

    Ethinyl estradiol/levonorgestrel is administered on Period 1 Day 1 and then again on Period 3 Day 1. Venetoclax is administered on Period 2 Day 1 and then daily thereafter.

    Drug: Venetoclax · Drug: ethinyl estradiol/levonorgestrel

Interventions

  • tablet; oral

    Also known as: ABT-199, GDC-0199, Venclexta

  • Drugethinyl estradiol/levonorgestrel

    tablet; oral

    Also known as: Levora

06

What researchers measure

Primary outcomes

  1. Tmax of Venetoclax

    Time to maximum plasma concentration (Tmax) of Venetoclax.

    Time frame: Up to approximately 59 days after initial study drug dose

  2. Tmax of (ethinyl estradiol) EE/Levonorgestrel

    Time to maximum plasma concentration (Tmax) of EE/Levonorgestrel

    Time frame: Up to approximately 59 days after initial study drug dose

  3. Cmax of Venetoclax

    Maximum plasma concentration (Cmax) of Venetoclax

    Time frame: Up to approximately 59 days after initial study drug dose

  4. Cmax of EE/Levonorgestrel

    Maximum plasma concentration (Cmax) of EE/Levonorgestrel

    Time frame: Up to approximately 59 days after initial study drug dose

  5. t1/2 of Venetoclax

    Terminal phase elimination half-life (t1/2) of Venetoclax.

    Time frame: Up to approximately 59 days after initial study drug dose

  6. t1/2 of EE/Levonorgestrel

    Terminal phase elimination half-life (t1/2) of EE/Levonorgestrel

    Time frame: Up to approximately 59 days after initial study drug dose

  7. AUCt of Venetoclax

    Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt) of Venetoclax

    Time frame: Up to approximately 59 days after initial study drug dose

  8. AUCt of EE/Levonorgestrel

    Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt) of EE/Levonorgestrel

    Time frame: Up to approximately 59 days after initial study drug dose

  9. AUCinf of EE/Levonorgestrel

    AUC from time 0 extrapolated to infinite time (AUCinf) of EE/Levonorgestrel.

    Time frame: Up to approximately 59 days after initial study drug dose

07

Study locations

1 of 4 sites recruiting
  • Duplicate_Henry Ford Health System /ID# 209090
    Detroit, Michigan 48202, United States
    Completed

    Not enrolling at this site.

  • Dartmouth-Hitchcock Medical Center /ID# 169097
    Lebanon, New Hampshire 03756, United States
    Completed

    Not enrolling at this site.

  • Gabrail Cancer Center Research /ID# 207039
    Canton, Ohio 44718, United States
    Completed

    Not enrolling at this site.

  • Peter MacCallum Cancer Centre-East Melbourne /ID# 225247
    East Melbourne, Victoria 3002, Australia
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Mar 2026, 79 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 79 months is above that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 15, 2018
StartActual
Jul 30, 2019
Primary completionEst.
Mar 21, 2026
CompletionEst.
Mar 21, 2026
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03557619
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
Jul 30, 2019
Primary completion
Mar 21, 2026 (estimated)
Completion
Mar 21, 2026 (estimated)
Last update
Aug 29, 2024

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion